Researchers Launch First Study of In Vivo CRISPR Therapy in Humans

Gene Editing Services

Ubigene has modified over 5000 genes from more than 200 cell lines with our exclusive innovation CRISPR-U™ technology. At the same time, we already provide customers with high quality gene-editing tools for cell or animal research worldwide.

Stable Cell Lines

Knockout Cell Lines

Knockin Cell Lines

Overexpression Cell Lines

Knockdown Cell Lines

iPSC and ESC Gene editing

Cloning Services

Knockout Plasmid

Point Mutation Plasmid

Knockin Plasmid

Overexpression Plasmid

Knockdown Plasmid

Virus Packaging

Lentivirus Packaging

Adenovirus Packaging

Adeno-associated Virus Packaging

CRISPR Library

CRISPR Library In-stock

Customized CRISPR Library

CRISPR Library Screening

Microbe

Gene-editing E.coli

Gene-editing Salmonella

Gene-editing P. aeruginosa

Gene-editing S. aureus

Cell Assay

Cell Proliferation

Cell Migration and Invasion

Cell Cycle

Cell Apoptosis

Detection of Marker Protein Expression

Cytokine Secretion and Enzyme Activity Test

Cytotoxicity Test

EZ-editor™
Gene-editing Series Products

With 14 years of experience, Ubigene has exclusively innovated and developed 6 product lines, fullfilling all kinds of needs from researchers. Experiment process simplified, efficiency improved, achieving our aim of 'Make genome editing easier'!

Red Cotton™ gRNA Plasmid Bank

Regular Plasmid

Lentiviral Plasmid

EZ-editor™ Culture Medium

Transfection Culture Medium

Cell Monoclonal Culture Medium

EZ-Stem™ Cell Culture Medium

EZ-cryo™ Cell Freezing Medium

Knockout-cell-lysate

KO cell lysates (clone)

KO cell lysates (pool)

EZ-editor™ Cell Line

KO Cell Lines

Wild-type Cell Lines

Cas9 Stable Cell Lines

Luciferase Stable Cell Lines

EGFP Stable Cell Lines

EZ-editor™ Kits

Monoclone Genotype Validation Kit (extraction free)

EZ-editor™ Gene Knockout kit

Mouse Genotyping Kit

Lentiviral Packaging Kit

Lentivirus

IVD positive controls

Point Mutation gDNA/Cell Line

Red Cotton Gene knockout Project

Ubigene exclusive KO Cell Line Bank, over 5000 KO cell lines, covering thousands of genes from 8 popular signaling pathways and nearly 100 diseases.

Red Cotton CRISPR Gene Editing Designer

Gene Editing Cell Designer

Gene Editing Point Mutation Designer

Gene Editing Microbe Designer

Gene Editing Tool Kit

Red Cotton Gene knockout Project

Location：Home > About Us > Blogs >

Contact us✖

* Name：

Institution：

* Project Description：

* How would you like us to contact you?

* E-mail：

Phone：

WhatsAPP：

FaceBook Messenger：

Our Solution Specialists will contact you within 2 business days. Of course, you can also tell us when you would like to be contacted:

Select：

Researchers Launch First Study of In Vivo CRISPR Therapy in Humans

A trial is recruiting patients to test the gene-editing technology's ability to treat an inherited form of blindness caused by a mutation in the CEP290 gene.

People with a rare form of inherited blindness are being enrolled for the world's first in vivo human study of a CRISPR-based therapy, the Associated Press reported on July 25. The experimental treatment, developed by Massachusetts-based genome-editing company Editas Medicine and Ireland-based pharmaceutical firm Allergan, removes a deleterious mutation from cells in patients' retinas, and will be tested in 18 adults and children later this year.

"Today marks an important day for the inherited retinal disease community," Ben Yerxa, CEO of nonprofit Foundation Fighting Blindness, says in a press statement. "We are very excited to have another potentially life changing medicine enter the clinic and join Allergan and Editas in celebrating this milestone."

The therapy is designed to treat people with a particular form of a disease known as Leber congenital amaurosis that is caused by a point mutation in a gene called CEP290. This particular mutation leads to abnormal splicing and dysfunctional production of the CEP290 protein, which plays an important role in the photoreceptors in the eye. Once injected under the retina, the therapy should cut out the mutation in the gene and restore normal splicing.

The trial differs from previous attempts to use CRISPR for therapeutic purposes, which have either been ex vivo (using cells extracted from patients and then replaced post-editing), or, controversially, in embryonic cells. Because the treatment is only applied locally to somatic cells, the changes it makes will not be heritable.

✖

Phone

✖无法在这个位置找到： global_components/subscribe.htm

Researchers Launch First Study of In Vivo CRISPR Therapy in Humans

Subscribe Us

Contact us✖

Researchers Launch First Study of In Vivo CRISPR Therapy in Humans

Gene Editing Services

EZ-editor™ Products